NCT00471432 2023-08-04
OGX-011 and Docetaxel in Treating Patients With Metastatic or Locally Recurrent Solid Tumors
Canadian Cancer Trials Group
Phase 1 Completed
Clinical Trials
11 trialsNCT00114218 2019-01-08
Gemcitabine and Docetaxel in Treating Patients With Recurrent or Persistent Uterine Cancer
GOG Foundation
Phase 2 Completed
NCT00569673 2018-07-18
Docetaxel, Trabectedin, and G-CSF or Pegfilgrastim in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer
GOG Foundation
Phase 2 Completed
NCT00041093 2018-01-10
Docetaxel in Treating Patients With Persistent or Recurrent Cervical Cancer
GOG Foundation
Phase 2 Completed
NCT00872989 2016-12-19
S0904: Docetaxel With or Without Vandetanib in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
SWOG Cancer Research Network
Phase 2 Completed
NCT00031629 2016-12-08
Combination Chemotherapy and Filgrastim or Pegfilgrastim in Treating Patients With Recurrent or Persistent Cancer of the Uterus
GOG Foundation
Phase 2 Completed
NCT00066456 2016-02-11
Radiation Therapy to the Abdomen Plus Docetaxel in Treating Patients With Recurrent or Persistent Advanced Ovarian, Peritoneal, or Fallopian Tube Cancer
GOG Foundation
Phase 1 Completed
NCT00003120 2014-10-09
S9701 Paclitaxel in Treating Patients With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission
SWOG Cancer Research Network
Phase 3 Completed
NCT00085332 2014-01-13
Docetaxel in Treating Patients With Recurrent or Persistent Endometrial Carcinoma (Cancer)
GOG Foundation
Phase 2 Completed
NCT00004037 2013-04-11
Docetaxel in Treating Patients With Recurrent or Refractory Ovarian or Primary Peritoneal Cancer
GOG Foundation
Phase 2 Terminated
NCT00002903 2012-07-02
Docetaxel in Treating Patients With Recurrent or Refractory Germ Cell Cancer
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Completed